A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
NCT07843550 is a phase 1/2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is not yet recruiting. It studies Larotrectinib and Pembrolizumab in Solid Tumor. The registry lists an enrollment of 22 participants at 1 site in 1 country. The registry lists a start date of 1 Mar 2027 and a primary completion date of 13 Jul 2027. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT07843550 |
| Status | Not yet recruiting |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | M.D. Anderson Cancer Center |
| Enrollment | 22 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Solid Tumor |
| Drugs | Larotrectinib and Pembrolizumab |
| Start | 1 Mar 2027 |
| Primary completion | 13 Jul 2027 |
| Study completion | 13 Jul 2029 |
| Last update posted | 28 Sept 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT07843550
Each answer restates registry values shown on this page.
What is NCT07843550?
NCT07843550 is a phase 1/2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Larotrectinib and Pembrolizumab in Solid Tumor.
Is NCT07843550 recruiting?
As of 21 Nov 2026, it is not yet recruiting.
Who leads NCT07843550?
The registry names David Hong, MD (principal investigator, UT MD Anderson) as the overall official.
Where does NCT07843550 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT07843550 study?
The registered drug and biological interventions are Larotrectinib and Pembrolizumab.
When is NCT07843550 expected to complete?
The registry lists a primary completion date of 13 Jul 2027 and a study completion date of 13 Jul 2029. The sponsor last updated the record on 28 Sept 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.